Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;35(2):249-259.
doi: 10.1007/s10557-020-07037-2. Epub 2020 Jul 15.

Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective

Azita Hajhossein Talasaz  1   2 , Hessam Kakavand  3 , Benjamin Van Tassell  4   5 , Maryam Aghakouchakzadeh  3 , Parham Sadeghipour  6 , Steven Dunn  7 , Babak Geraiely  8
Affiliations
Review

Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective

Azita Hajhossein Talasaz et al. Cardiovasc Drugs Ther. 2021 Apr.

Abstract

Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.

Keywords: COVID-19; Cardiovascular; Drug–drug interactions; Pharmacotherapy; SARS-Cov2; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Fig. 1
Fig. 1
Cardiovascular complications of COVID-19 are illustrated herein
See this image and copyright information in PMC

References

    1. https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-rem.... Accessed 12 March 2020.
    1. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multi-organ response. Curr Probl Cardiol. 2020;45(8):100618. - PMC - PubMed
    1. W-j G, Ni Z-y HY, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. - PMC - PubMed
    1. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798–1800. - PMC - PubMed
    1. Ebinger JE, Shah PK. Declining admissions for acute cardiovascular illness: the Covid-19 paradox. J Am Coll Cardiol. 2020;1097(20):35394–35398. - PMC - PubMed

Substances

LinkOut - more resources